CinCor Pharma, Inc. - Common Stock (NQ:CINC)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 23, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CinCor Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Stocks That Hit 52-Week Lows On Friday ↗

December 02, 2022

On Friday, 72 companies hit new 52-week lows.

Via Benzinga

Hibbett, Enfusion And Some Other Big Stocks Moving Lower On Tuesday ↗

November 29, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

CinCor Pharma Sinks After Disappointing Data From Hypertension Trial ↗

November 28, 2022

Via Benzinga

Expert Ratings for CinCor Pharma ↗

October 28, 2022

Analysts have provided the following ratings for CinCor Pharma (NASDAQ:CINC) within the last quarter:

Via Benzinga

Where CinCor Pharma Stands With Analysts ↗

October 28, 2022

Within the last quarter, CinCor Pharma (NASDAQ:CINC) has observed the following analyst ratings:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 29, 2022

Via Benzinga

Why Shares Of Chinese Companies Are Trading Higher? Here Are 45 Stocks Moving In Tuesday's Mid-Day Session ↗

November 29, 2022

Gainers Otonomy, Inc. (NASDAQ: OTIC) shares surged 74.2% to $0.1866. Otonomy recently posted a Q3 loss of $0.18 per share.

Via Benzinga

US Stocks Edge Higher Following Monday's Sell-Off ↗

November 29, 2022

U.S. stocks traded slightly higher this morning, with the Dow Jones gaining more than 30 points on Tuesday. The blue-chip index dropped around 500 points on Monday.

Via Benzinga

What 4 Analyst Ratings Have To Say About CinCor Pharma ↗

October 28, 2022

Within the last quarter, CinCor Pharma (NASDAQ:CINC) has observed the following analyst ratings:

Via Benzinga

Expert Ratings for CinCor Pharma ↗

September 09, 2022

Within the last quarter, CinCor Pharma (NASDAQ:CINC) has observed the following analyst ratings:

Via Benzinga

4 Analysts Have This to Say About CinCor Pharma ↗

August 22, 2022

CinCor Pharma (NASDAQ:CINC) has observed the following analyst ratings within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022 ↗

November 29, 2022

Via Benzinga

FedEx To Rally Over 25%? Here Are 10 Other Price Target Changes For Tuesday ↗

November 29, 2022

Keybanc lowered Salesforce, Inc. (NYSE: CRM) price target from $210 to $200. . Keybanc analyst Michael Turits maintained an Overweight rating on the stock. Salesforce shares gained 0.5% to $154.45 in...

Via Benzinga

Dow Tumbles 450 Points; S&P 500 Falls 1.5% ↗

November 28, 2022

U.S. stocks traded lower toward the end of trading amid protests over COVID-19 restrictions in China. The Dow Jones dropped more than 450 points on Monday.

Via Benzinga

Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 28, 2022

Gainers Taboola.com Ltd. (NASDAQ: TBLA) shares gained 52.5% to $2.8050 after the company announced it entered into a 30-year exclusive commercial agreement with Yahoo.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 28, 2022

Via Benzinga

Stocks Stumbling After Thanksgiving Week ↗

November 28, 2022

The Dow Jones Industrial Average is extending its premarket losses, down 265 points at midday, as protests in China over the country's zero-Covid policy weigh on investor sentiment globally.

Via Talk Markets

Dow Tumbles Over 200 Points; Axsome Therapeutics Shares Spike Higher ↗

November 28, 2022

U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 200 points on Monday.

Via Benzinga

CinCor Pharma, Anavex Life Sciences And Some Other Big Stocks Moving Lower On Monday ↗

November 28, 2022

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Start Week On Lower Note, Dow Drops Over 100 Points ↗

November 28, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping more than 100 points on Monday.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 28, 2022

Via Benzinga

Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update

November 04, 2022

From CinCor Pharma Inc

Via GlobeNewswire

CinCor Reports Third Quarter Financial Results and Provides Corporate Update

November 03, 2022

From CinCor Pharma Inc

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022 ↗

October 28, 2022

Upgrades

Via Benzinga

3 Soaring Biotech Stocks That Could Climb Much Higher ↗

October 20, 2022

These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 20, 2022

Gainers CinCor Pharma (NASDAQ:CINC) shares moved upwards by 19.5% to $33.0 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 billion.

Via Benzinga

Analyst Ratings for CinCor Pharma ↗

September 09, 2022

Over the past 3 months, 5 analysts have published their opinion on CinCor Pharma (NASDAQ:CINC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Where CinCor Pharma Stands With Analysts ↗

September 09, 2022

Via Benzinga

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022 ↗

August 22, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.